Our results suggest that targeting excessive TRPV4 and RhoA pathway activity may hold therapeutic promise for patients with TRPV4 mutations and in other conditions associated with TRPV4 and RhoA dysregulation, such as traumatic brain injury, stroke, and pulmonary edema79–86. Here, RHOA is linked to Stroke.